Trials / Recruiting
RecruitingNCT07222436
Circulating Tumor DNA in High Risk Localized Prostate Cancer
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 24 (estimated)
- Sponsor
- University of Pittsburgh · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This prospective, non-therapeutic translational biomarker study will collect blood in patients with high risk localized prostate cancer prior to prostatectomy.
Detailed description
The Vogelstein lab has developed a highly sensitive, tumor-informed method of detecting circulating free DNA (cfDNA) shed by solid tumors. Plasma will be assayed for ctDNA using the SaferSeqS tumor-informed assay, employing DNA sequences derived from prostatectomy specimens. The abundance and molecular characteristics of ctDNA will be evaluated for a pilot group of 12-24 patients using an adaptive statistical design.
Conditions
Timeline
- Start date
- 2025-09-23
- Primary completion
- 2027-09-30
- Completion
- 2027-09-30
- First posted
- 2025-10-29
- Last updated
- 2025-10-29
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT07222436. Inclusion in this directory is not an endorsement.